Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Christie M. Ballantyne"'
A polygenic risk score of atrial fibrillation improves prediction of lifetime risk for heart failure
Autor:
Taryn Alkis, Xi Luo, Katherine Wall, Jennifer Brody, Traci Bartz, Patricia P. Chang, Faye L. Norby, Ron C. Hoogeveen, Alanna C. Morrison, Christie M. Ballantyne, Josef Coresh, Eric Boerwinkle, Bruce M. Psaty, Amil M. Shah, Bing Yu
Publikováno v:
ESC Heart Failure, Vol 11, Iss 2, Pp 1086-1096 (2024)
Abstract Aims Heart failure (HF) has shared genetic architecture with its risk factors: atrial fibrillation (AF), body mass index (BMI), coronary heart disease (CHD), systolic blood pressure (SBP), and type 2 diabetes (T2D). We aim to assess the asso
Externí odkaz:
https://doaj.org/article/ce72f0daf1734ab3a5fbf90a46faf51e
Autor:
Rebecca Vigen, Colby Ayers, Jarett Berry, Anand Rohatgi, Vijay Nambi, Christie M. Ballantyne, Torbjorn Omland, Christopher R. de Filippi, James de Lemos
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 13 (2024)
Background High‐sensitivity troponin I (hs‐cTnI) and T (hs‐cTnT) provide complementary information regarding cardiovascular disease risk. The explanation for their distinct risk profiles is incompletely understood. Methods and Results hs‐cTnI
Externí odkaz:
https://doaj.org/article/a9deaeb8daa74eefba531e086259a5f7
Autor:
Justin B. Echouffo‐Tcheugui, Sui Zhang, Roberta Florido, James S. Pankow, Erin D. Michos, Ronald B. Goldberg, Vijay Nambi, Gary Gerstenblith, Wendy S. Post, Roger S. Blumenthal, Christie M. Ballantyne, Josef Coresh, Elizabeth Selvin, Chiadi E. Ndumele
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 6 (2024)
Background It is unclear how metabolic syndrome (MetS) and diabetes affect Gal‐3 (galectin 3) levels and the resulting implications for heart failure (HF) risk. We assessed relationships of MetS and diabetes with Gal‐3, and their joint associatio
Externí odkaz:
https://doaj.org/article/2ae882273ed64fc8ac591dde05d50866
Autor:
Cady Smith, Jarett D. Berry, Rebecca Scherzer, James A. de Lemos, Vijay Nambi, Christie M. Ballantyne, Richard L. Kravitz, Anthony A. Killeen, Joachim H. Ix, Michael G. Shlipak, Simon B. Ascher
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 6 (2024)
Background Among individuals with hypertension and low diastolic blood pressure (DBP), the optimal BP target remains controversial due to concerns that BP lowering may reduce coronary perfusion. We determined the impact of intensive BP control among
Externí odkaz:
https://doaj.org/article/5343198ad31e4809b501ba574d28ffdf
Autor:
Asem I. Fitian, Michael C. Shieh, Olga A. Gimnich, Tatiana Belousova, Addison A. Taylor, Christie M. Ballantyne, Jean Bismuth, Dipan J. Shah, Gerd Brunner
Publikováno v:
Journal of Cardiovascular Development and Disease, Vol 11, Iss 6, p 181 (2024)
Background: Extracellular volume fraction (ECV), measured with contrast-enhanced magnetic resonance imaging (CE-MRI), has been utilized to study myocardial fibrosis, but its role in peripheral artery disease (PAD) remains unknown. We hypothesized tha
Externí odkaz:
https://doaj.org/article/6ffbb52646a943fd86fc48936759eac7
Autor:
William S. Weintraub, Deepak L. Bhatt, Zugui Zhang, Sarahfaye Dolman, William E. Boden, Adam P. Bress, Brandon K. Bellows, Catherine G. Derington, Sephy Philip, Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Jean‐Claude Tardif, Christie M. Ballantyne, Paul Kolm
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 1 (2024)
Background In 3146 REDUCE‐IT USA (Reduction of Cardiovascular Events With Icosapent Ethyl Intervention Trial USA) participants, icosapent ethyl (IPE) reduced first and total cardiovascular events by 31% and 36%, respectively, over 4.9 years of foll
Externí odkaz:
https://doaj.org/article/dc8430b3b4ce4e8a958569552e9dcca3
Autor:
Samuel S. Gidding, Christie M. Ballantyne, Marina Cuchel, Sarah de Ferranti, Lisa Hudgins, Allison Jamison, Mary P. McGowan, Amy L. Peterson, Robert D. Steiner, Melissa K. Uveges, Yunshu Wang
Publikováno v:
Global Heart, Vol 19, Iss 1, Pp 43-43 (2024)
Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately one in 300,000 people. The disorder is characterized by extremely high, life-threatening levels of low-density lipoprotein (LDL) cholester
Externí odkaz:
https://doaj.org/article/d2058999a0ea4372bd20514d6dc45bef
Autor:
Austin Deets, Parag H. Joshi, Alvin Chandra, Kavisha Singh, Amit Khera, Salim S. Virani, Christie M. Ballantyne, James D. Otvos, Robin P. F. Dullaart, Eke G. Gruppen, Margery A. Connelly, Colby Ayers, Ann Marie Navar, Ambarish Pandey, John T. Wilkins, Anand Rohatgi
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 21 (2023)
Background High‐density lipoprotein (HDL) particle concentration likely outperforms HDL cholesterol in predicting atherosclerotic cardiovascular events. Whether size‐based HDL subspecies explain the atheroprotective associations of HDL particle c
Externí odkaz:
https://doaj.org/article/3ef89734bb2f46c88e6ec6de3a77d86f
Autor:
Michael D. Shapiro, Tariq M. Haddad, Howard S. Weintraub, Seth J. Baum, Khaled AbdulNour, Vadim Paluy, Wess Boatwright, Auris Browne, Imran Ayaz, Cheryl A. Abbas, Christie M. Ballantyne
Publikováno v:
American Journal of Preventive Cardiology, Vol 15, Iss , Pp 100552- (2023)
Therapeutic Area: ASCVD/CVD Risk Reduction Background: Elevated lipoprotein(a) [Lp(a)] is the most common inherited dyslipidemia leading to an increased risk of atherosclerotic cardiovascular disease (ASCVD). Several cohort studies have reported elev
Externí odkaz:
https://doaj.org/article/8d7dd21bc5624b9791f2cab6f92bbfb4
Autor:
Laura H. Gunn, Ailsa J. McKay, Amy Feng, Michael J. Louie, Christie M. Ballantyne, Kausik K. Ray
Publikováno v:
Atherosclerosis Plus, Vol 49, Iss , Pp 20-27 (2022)
Background and aims: Cardiovascular outcomes trials have demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk for future cardiovascular events. We assessed the potential cardiovascular benefits of bempedoic acid thr
Externí odkaz:
https://doaj.org/article/f6587704d18d43d495fcf411a405f384